-
Mashup Score: 15SABCS24 ONCOALERT | ONCOBITES - 5 day(s) ago
In an interview, Dr. Agostinetto delves into the findings of Dr. Souza, who shares the results of his research explaining why larotrectinib is positioned as an effective and safe treatment option for patients with TRK fusion breast cancer. Dr. Cristiano de P á dua Souza MD, Jules Bordet Institute, Brussels,
Source: www.oncobites.tvCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 18
This observational study investigates the association of adenoma detection rates among physicians who perform colonoscopy and postcolonoscopy colorectal cancer incidence.
Source: jamanetwork.comCategories: General Medicine News, Oncologists1Tweet-
Adenoma Detection Rates by Physicians and Subsequent Colorectal Cancer Risk out on @JAMANetwork https://t.co/cSJUQq1C57 This observational study investigated the relationship between improved adenoma detection rates (ADR) among physicians and the incidence of postcolonoscopy… https://t.co/iPnLbCCFBB https://t.co/03sKB7eRDz
-
-
Mashup Score: 1The OncoAlert Newsletter is NOW OUT Click to Register - 5 day(s) ago
The OncoAlert Newsletter is now out for June 23-29, 2023
Source: www.OncoAlert360.comCategories: General Medicine News, Onc News and JournalsTweet-
RT @BenWestphalen: Out today 💥 The new @OncoAlert 🚨 #newsletter - if you don’t want to miss out: register at https://t.co/AxMKHsMAQC 🌐
-
-
Mashup Score: 36Meet Dr. Toni K. Choueiri - 6 day(s) ago
Dr. Toni K. Choueiri shares how hard work and focus keeps him from getting discouraged or giving up when times get hard.
Source: connection.asco.orgCategories: General Medicine News, Oncologists1Tweet-
Meet the Heart & Soul of the @OncoAlert 🚨Network Great Oncologist/Amazing friend/Founding Faculty interview at ASCO Connection found here👇👇 https://t.co/ieivipg9zp Our dear friend @DrChoueiri 🇺🇸serves as the director of the Lank Center for Genitourinary Oncology at the… https://t.co/OYpDmgqWT2 https://t.co/rxPM45qS7U
-
-
Mashup Score: 13
Join this webinar on Wednesday 22 January 2025, 19:00-20:00 CET, where Etienne Brain, Evandro de Azambuja, Valentina Guarneri, Cristina Saura and Hans Wildiers will discuss the management of hormone receptor-positive, HER2-negative metastatic breast cancer. EACCME accreditation for attending the live webinar has been applied for.
Source: us02web.zoom.usCategories: General Medicine News, Oncologists1Tweet-
Join our collaborators at @MirrorsMed for a webinar on Wednesday, 22 January 2025, from 19:00 to 20:00 CET Optimising the management of HR+ HER2- met #BreastCancer SIGN UP HERE https://t.co/WpqVGhyvhl as experts @EtienneB66 @E_de_Azambuja Valentina Guarneri,… https://t.co/aqJPO0biHr https://t.co/cZGLdYrqMW
-
-
Mashup Score: 14High5 Oncology TV: SABCS 2024 - 6 day(s) ago
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreiche
Source: high5oncology.tvCategories: General Medicine News, Oncologists1Tweet-
EMBER3 Presented at #SABCS24 and out on @NEJM Report with Peter Fasching ( @high5md ) https://t.co/e8KCGT3rdi Imlunestrant is a novel oral medication that targets and degrades estrogen receptors (ER), even in breast cancers resistant to traditional hormone therapies due to ER… https://t.co/Fhts3V34dQ https://t.co/np8nNlrxbo
-
-
Mashup Score: 19High5 Oncology TV: SABCS 2024 - 7 day(s) ago
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreiche
Source: high5oncology.tvCategories: General Medicine News, Oncologists1Tweet-
The PADMA trial presented at #SABCS24 Report with Alessandra Gennari @ALEDIGNUS12 ( @high5md ) https://t.co/F00fzS12q8 Demonstrated that palbociclib plus endocrine therapy significantly improves time to treatment failure and progression-free survival compared to chemotherapy… https://t.co/mBxEOMhlIN https://t.co/rmE00SHgrz
-
-
Mashup Score: 25Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer. - 7 day(s) ago
Epidermal growth factor receptor (EGFR) mutations are key oncogenic drivers in lung adenocarcinoma (LUAD), predominantly affecting Asian, non-smoking, and female populations. While common mutations, such as exon 19 deletions and L858R, respond well to tyrosine kinase inhibitors (TKIs), uncommon EGFR mutations and compound variants exhibit variable treatment responses. This study aims to compare clinical characteristics and molecular profiles of patients with common, uncommon, and compound EGFR mutations, assessing their implications for therapy outcomes.
Source: www.jto.orgCategories: General Medicine News, Oncologists1Tweet-
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer #NSCLC out in JTO https://t.co/mLSjUXs5qh This study investigates the clinical and molecular differences among common, uncommon, and compound EGFR… https://t.co/nwp3OM43DY https://t.co/du9nL4SZlS
-
-
Mashup Score: 24APCCC Diagnostics 2025 - APCCC - 7 day(s) ago
The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid and tissue based biomarkers as well as the recent introduction of PSMA PET imaging have significantly advanced the field, challenging some of the old grounds of truth. The introduction of the Advanced Prostate Cancer Consensus Conference (APCCC) in 2015 represents a milestone of establishing clinical consensus in the
Source: apccc.orgCategories: General Medicine News, Oncologists1Tweet-
Dear Colleagues A warm invitation to JOIN US at #APCCCDiagnostics25 A HYBRID Meeting (In Person & Live) in Lugano Switzerland February 27-28, 2025 REGISTER: https://t.co/liXpdhy66c Enjoy Early Bird Registration, NOW OPEN ONLINE REGISTRATION FOR LMIC's FREE‼️ OncoAlert 🚨Will… https://t.co/UyKObpyq07 https://t.co/pPhDUcVQN5
-
-
Mashup Score: 19High5 Oncology TV: SABCS 2024 - 7 day(s) ago
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreiche
Source: high5oncology.tvCategories: General Medicine News, Oncologists1Tweet-
The PADMA trial presented at #SABCS24 Report with Alessandra Gennari @ALEDIGNUS12 ( @high5md ) https://t.co/F00fzS12q8 Demonstrated that palbociclib plus endocrine therapy significantly improves time to treatment failure and progression-free survival compared to chemotherapy… https://t.co/mBxEOMhlIN https://t.co/rmE00SHgrz
-
Join our collaborators at @OncobitesTv for an interview featuring @DrCrisPadua as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Link: https://t.co/k9RIIRx7nl Dr. @ElisaAgostinett Elisa Agostinetto from the Jules Bordet Institute in… https://t.co/YPDzOVivRA https://t.co/I59Ldib4g1